

Catalog# BP- 50504

Adalimumab Biosimilar (Human TNF alpha Monoclonal Antibody)

Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNF α , inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNF α) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.

Product Details	
CAS No.	331731-18-1
Species Reactivity	Human
Source	Adalimumab biosimilar CHO stable cell line
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Adalimumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human TNF alpha
Purity	>95%
Molecular Weight	145.43 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 μ M filtered solution, pH 5.2
Storage conditions	4°C for short time, -20°C or -80°C for long time.